Caprotec Bioanalytics said this week that it has successfully completed a collaboration with Roche that used the company's Capture Compound Mass Spectroscopy platform to analyze the interaction of an undisclosed drug candidate with human protein targets.

Caprotec said it was able to demonstrate that among the protein targets binding specifically to the drug in question were proteins showing activity in pathways commensurate with the drug candidate's phenotypic profile.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.